On Feb 2, 2026, Lau et al. published a paper in Frontiers in Immunology titled " Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression.' The research team addresses a critical bottleneck in chimeric antigen receptor (CAR) T-cell therapy: the biochemical vulnerability of engineered cells to the tumor microenvironment (TME). While CAR-T therapy has revolutionized the treatment of B-cell malignancies, many patients experience relapses due to poor T-cell persistence. The authors demonstrate that galectin-3 (Gal-3) acts as a potent extrinsic suppressor that triggers CAR-T cell death and dysfunctional cytokine signaling. By utilizing synthetic glycobiology to enforce the expression of α2,6-sialyltransferase 1 (ST6GAL1), the team successfully shielded CAR-T cells from Gal-3 binding. This "glycan-masking" strategy enhanced the survival, expansion, and anti-tumor efficacy of CAR-T cells in vivo, providing a transformative blueprint for the next generation of adoptive cell therapies.

The Invisible Sugar Shield: Glycobiology in Cancer Immunotherapy

The clinical success of anti-CD19 CAR-T cells in treating diffuse large B-cell lymphoma (DLBCL) is often overshadowed by the fact that the majority of patients do not achieve durable, long-term remission. To date, synthetic biology efforts to improve these "living drugs" have focused almost exclusively on the protein-centric architecture of the CAR construct, optimizing scFv affinity, hinge lengths, or co-stimulatory domains like 4-1BB and CD28. However, this focus ignores a fundamental biological layer: the glycome. Every CAR-T cell is enveloped in a dense forest of complex carbohydrates (glycans) that dictate how the cell interacts with its environment.

Galectins are a family of β-galactoside-binding lectins that serve as critical checkpoints in immune regulation. Among them, Gal-3 is frequently upregulated in the lymphoma microenvironment. Gal-3 functions by "cross-linking" surface glycoproteins on T cells, creating lattices that can physically sequester receptors or trigger intracellular signaling pathways leading to programmed cell death (apoptosis) and exhaustion.

The research team hypothesized that the standard manufacturing process for CAR-T cells, involving intensive ex vivo activation and expansion, might inadvertently alter the T cell's glycan signature, leaving it "naked" and susceptible to Gal-3-mediated suppression upon re-infusion. Specifically, they focused on α2,6-sialylation, a terminal sugar modification that acts as a natural biological "off-switch" for galectin binding. By understanding and manipulating this glycan checkpoint, the researchers aimed to engineer a more resilient immune cell capable of thriving in the hostile chemical landscape of a tumor.

Deciphering the Glycan Vulnerability of CAR-T Cells

The investigation began with a clinical assessment of the "enemy" landscape. By analyzing serum from 31 DLBCL patients, the researchers confirmed that Gal-3 levels were elevated compared to healthy donors, establishing Gal-3 as a relevant systemic and local threat in lymphoma. To understand why CAR-T cells might be vulnerable, the team performed high-sensitivity MALDI-TOF mass spectrometry-based N-glycomics on anti-CD19 CAR-T cells at the "end-of-manufacture" stage. The findings were revelatory:

• Glycan Profiling: Manufactured CAR-T cells displayed an abundance of Gal-3 ligands (complex N-glycans with terminal galactose).
• Enzymatic Deficiency: Quantitative PCR and flow cytometry revealed that the enzyme responsible for capping these ligands, ST6GAL1, was downregulated during the T-cell expansion process.
• Functional Consequence: When these CAR-T cells were exposed to recombinant Gal-3 in vitro, they exhibited a sharp, dose-dependent increase in apoptosis (measured via Annexin V/PI staining). Furthermore, Gal-3 exposure skewed the cytokine profile of the CAR-T cells, inducing high levels of IL-5, a cytokine often associated with poor prognosis and Th2-like dysfunctional responses in oncology.

Fig.1 Anti-CD19 CAR-T cells displayed elevations in tri-antennary N-glycans and poly-LacNAc and low levels of α2,6 sialylation. (Lau, et al., 2026)

Synthetic Enforcement of ST6GAL1 for Glycan Re-modeling

Having identified the lack of α2,6-sialylation as a biochemical "Achilles' heel," the researchers turned to synthetic biology to fix it. They engineered a lentiviral vector to overexpress ST6GAL1 in coordination with the anti-CD19 CAR construct.

• Surface Re-engineering: The resulting ST6OE CAR-T cells showed a massive increase in α2,6-sialic acid residues on their surface.
• Blocking Gal-3 Binding: Using recombinant Gal-3 binding assays, the team demonstrated that this enzymatic "capping" reduced Gal-3 binding by over 80%. The sialic acid acted as a protective mask, preventing the galectin from reaching its galoside targets.
• Preservation of Antigen Recognition: A critical concern in glycoengineering is whether changing the cell surface sugar coat interferes with the CAR's ability to bind its target. The study confirmed that ST6OE CAR-T cells retained identical binding affinity for CD19-bearing tumor cells, proving that the glycan modification was non-disruptive to the primary therapeutic mechanism.

In Vivo Validation and Enhanced Anti-Tumor Efficacy

The ultimate test of the glycoengineering strategy took place in a humanized mouse model of Nalm6 lymphoma, an environment characterized by suppressive galectin signaling.

• Superior Persistence: ST6OE CAR-T cells demonstrated significantly higher persistence in the blood and spleen of treated mice compared to conventional CAR-T cells. While the control CAR-T cells began to dwindle after 7-10 days, the glycoengineered cells continued to expand.
• Enhanced Tumor Clearance: The survival curves were definitive. Mice treated with ST6OE CAR-T cells showed more rapid and sustained tumor regression. The "glycan-shielded" cells were able to resist the apoptotic signals of the TME, allowing them to maintain their cytotoxic function for longer periods.
• Resistance to IL-5 Induction: Analysis of the systemic cytokine environment showed that ST6OE CAR-T cells did not produce the dysfunctional IL-5 surge seen in conventional CAR-T groups, suggesting a more robust and favorable "effector" phenotype.

Fig.2 CAR-T cells exhibited potent in vivo anti-tumor activity and persisted longer in vivo than conventional CAR-T cells. (Lau, et al., 2026)

Discussion and Innovations

• The "Glycan Checkpoint" Discovery
  This study is among the first to move beyond protein-protein interactions (like PD-1/PD-L1) to identify a glycan-lectin checkpoint as a major determinant of CAR-T cell fate. It highlights that the metabolic and enzymatic state of a cell during manufacture directly impacts its therapeutic "fitness" in the patient.
• Intrinsic vs. Extrinsic Resistance
  Traditional CAR-T optimization focuses on intrinsic factors (e.g., signaling domains). This paper innovates by targeting extrinsic resistance, the ability of the cell to ignore suppressive "stop" signals from the tumor microenvironment. By modifying the cell surface enzymatically, the researchers created a cell-autonomous defense system.
• ST6GAL1 as a Synthetic Biology Tool
  The use of ST6GAL1 as a "shielding" transgene is a significant innovation. It demonstrates that metabolic enzymes are used as transcription factors or receptors to program cell behavior. This opens the door for using other glycosyltransferases to "tune" immune cell trafficking, adhesion, and survival.
• Addressing Manufacturing-Induced Vulnerability
  The paper provides a cautionary tale for the industry: the very process of making CAR-T cells makes them weaker. By identifying the loss of ST6GAL1 during expansion, the authors suggest that glycoengineering could become a standard "quality control" step or a routine enhancement in commercial manufacturing protocols.

GlycoChas™ Cells at CD BioGlyco

Conclusion

The study by Lau and colleagues represents a masterclass in interdisciplinary research, bridging the gap between complex glycomics and clinical immunotherapy. By demonstrating that Gal-3 is a primary orchestrator of CAR-T cell failure through its interaction with unsialylated surface glycans, the team has identified a previously "invisible" barrier to cancer cure.

The innovation of ST6OE CAR-T cells, which utilize the ST6GAL1 enzyme to mask themselves with sialic acid, proves that we can biochemically arm immune cells against the tumor's defenses. These glycoengineered cells do not just recognize the tumor better; they survive it better. As the field of synthetic glycobiology continues to mature, this strategy of "glycan-masking" will likely become a cornerstone of adoptive cell therapy, enabling treatments to overcome the immunosuppressive "sugar-code" of the tumor microenvironment and achieve the long-sought goal of durable, lifelong remission for cancer patients.